68.49 USD
+0.01 (+0.01%)
68.49 USD
0 (0%)
Taking everything into account, GBT scores 2 out of 10 in our fundamental rating. GBT was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of GBT have multiple concerns. While showing a medium growth rate, GBT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- GBT had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.05% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -127.41% | ||
| PM (TTM) | -137.3% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, GBT has more shares outstanding
- GBT has a worse debt/assets ratio than last year.
2.2 Solvency
- GBT has an Altman-Z score of 1.24. This is a bad value and indicates that GBT is not financially healthy and even has some risk of bankruptcy.
- GBT has a Debt/Equity ratio of 4.92. This is a high value indicating a heavy dependency on external financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.24 |
ROIC/WACCN/A
WACC10.15%
2.3 Liquidity
- A Current Ratio of 6.88 indicates that GBT has no problem at all paying its short term obligations.
- GBT has a Quick Ratio of 6.17. This indicates that GBT is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.88 | ||
| Quick Ratio | 6.17 |
3. Growth
3.1 Past
- GBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.51%.
- Looking at the last year, GBT shows a very strong growth in Revenue. The Revenue has grown by 42.53%.
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%50.46%
3.2 Future
- Based on estimates for the next years, GBT will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.02% on average per year.
- GBT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.11% yearly.
EPS Next Y2.94%
EPS Next 2Y18.02%
EPS Next 3Y21.63%
EPS Next 5Y9.02%
Revenue Next Year47.16%
Revenue Next 2Y50.99%
Revenue Next 3Y48.16%
Revenue Next 5Y48.11%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- GBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year GBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -15.98 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as GBT's earnings are expected to grow with 21.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y21.63%
5. Dividend
5.1 Amount
- No dividends for GBT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GLOBAL BLOOD THERAPEUTICS IN / GBT FAQ
What is the fundamental rating for GBT stock?
ChartMill assigns a fundamental rating of 3 / 10 to GBT.
What is the valuation status of GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?
ChartMill assigns a valuation rating of 0 / 10 to GLOBAL BLOOD THERAPEUTICS IN (GBT). This can be considered as Overvalued.
How profitable is GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?
GLOBAL BLOOD THERAPEUTICS IN (GBT) has a profitability rating of 3 / 10.
What is the financial health of GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?
The financial health rating of GLOBAL BLOOD THERAPEUTICS IN (GBT) is 4 / 10.